PUT - SPRINTER OPEN END - ELI LILLY & CO | Real-time Boerse Frankfurt Warrants 08:24:33 03/06/2024 pm IST | ||
| 16.34 EUR | -8.97% |
|
| 1 month | -16.98% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 03/24/03 | 16.34 | -8.97% |
| 31/24/31 | 17.95 | +1.58% |
| 30/24/30 | 17.67 | -2.64% |
| 29/24/29 | 18.15 | -4.82% |
| 28/24/28 | 19.07 | +6.36% |
Real-time Boerse Frankfurt Warrants
Last update June 03, 2024 at 08:24 pm IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VD1JJ8 |
| ISIN | DE000VD1JJ87 |
| Date issued | 05/03/2024 |
| Strike | 1,007 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 20.17 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 26.84 € |
|---|---|
| Lowest since issue | 16.34 € |
| Spread | 0.03 € |
| Spread % | 0.18% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
820.3
USD
Average target price
852.5
USD
Spread / Average Target
+3.92%
- Stock Market
- Certificates
- Certificat
